Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

BiTEs, CAR T-Cell Therapy Enhance ALL Armamentarium, But Questions Remain

January 23rd 2020

Lloyd Damon, MD, discusses the evolution of the treatment paradigm in acute lymphoblastic leukemia.

Polatuzumab Vedotin Approved in Europe for Relapsed/Refractory DLBCL

January 22nd 2020

The European Commission has granted a conditional marketing authorization to polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma who are ineligible for hematopoietic stem cell transplant.

Dr. Mims on the Emergence of Targeted Therapy in AML

January 22nd 2020

Alice S. Mims, MD, discusses the emergence of targeted therapy in acute myeloid leukemia treatment.

Dr. Moskowitz on Important Updates in Hodgkin Lymphoma

January 21st 2020

Alison J. Moskowitz, MD, discusses important updates in Hodgkin lymphoma.

ASH 2019 Data Cement Current Treatment Approaches in Hodgkin, T-Cell Lymphoma

January 21st 2020

Weiyun Z. Ai, MD, PhD, discusses some of the most pivotal advances that have been made in the fields of T-cell lymphoma and Hodgkin lymphoma in recent years.

Targeting the Hedgehog Pathway Holds Promises and Pitfalls

January 18th 2020

Although small molecule inhibitors of the Hedgehog signaling pathway have transformed the treatment paradigm for advanced basal cell carcinoma, the most common form of skin cancer, efforts to expand their use to other tumor types have proved elusive.

Dr. Brown on the Success of Blinatumomab in the AALL 1331 Trial

January 17th 2020

Patrick Brown, MD, discusses the encouraging results of blinatumomab (Blincyto) in the AALL1331 trial.

Dr. Koff on Systemic Therapy Options in Follicular Lymphoma

January 17th 2020

Jean L. Koff, MD, MS, discusses systemic therapies in follicular lymphoma.

NICE Rejects Treatments for Head and Neck Cancer and AML

January 16th 2020

The United Kingdom’s National Institute for Health and Care Excellence has issued guidelines recommending against pembrolizumab for use in treatment-naïve patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score of ≥1.

Dr. Mims on Developed Mutations in AML

January 15th 2020

Alice S. Mims, MD, discusses developed resistance in acute myeloid leukemia.

Dr. Allen on Treatment Options in Advanced-Stage Hodgkin Lymphoma

January 13th 2020

Pamela Blair Allen, MD, MSc, discusses treatment options in advanced-stage Hodgkin lymphoma.

OSUCCC-James Oncologists Share Ongoing Research Efforts in Hematologic Malignancies

January 11th 2020

Experts from The Ohio State University Comprehensive Cancer Center–James highlighted exciting research being conducted at their institution.

Dr. Arellano on Managing Older Patients With AML

January 11th 2020

Martha L. Arellano, MD, discusses the management of older patients with acute myeloid leukemia.

Long-Term Follow-Up of Acalabrutinib in Patients With MCL and CLL

January 10th 2020

Kellie Ryan, MPH, discusses the importance of long-term follow-up with acalabrutinib in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).

FDA Places Partial Hold on Lacutamab Trial in Advanced T-Cell Lymphoma

January 10th 2020

The FDA has placed a partial clinical hold on the TELLOMAK trial, which is evaluating the efficacy and safety of lacutamab in patients with advanced T-cell lymphoma.

Dr. Brammer on the Importance of MRD in Relapsed/Refractory ALL

January 10th 2020

Jonathan E. Brammer, MD, discusses the importance of achieving minimal residual disease negativity in relapsed/refractory acute lymphoblastic leukemia.

Loncastuximab Tesirine Shows Encouraging ORR in Relapsed/Refractory DLBCL

January 9th 2020

Loncastuximab tesirine demonstrated an overall response rate of 45.5% in patients with relapsed/refractory diffuse large B-cell lymphoma, including those who are difficult to treat.

Targeted Therapy Approvals Spur Increased Biomarker Research in AML

January 9th 2020

Alice Mims, MD, discusses biomarker research and therapeutic developments in acute myeloid leukemia.

Relapsed/Refractory ALL Paradigm Rapidly Evolving With Novel Agents

January 9th 2020

Jonathan E. Brammer, MD, discusses the role of minimal residual disease and transplant in acute lymphoblastic leukemia, as well as the introduction of CAR T-cell therapy and other novel agents to the armamentarium.

Dr. Mims on Performing Molecular Profiling at Diagnosis in AML

January 9th 2020

Alice S. Mims, MD, discusses up front molecular profiling in patients with newly diagnosed acute myeloid leukemia.